Skip to playerSkip to main content
After-the-fact Expert
Alnylam Pharmaceuticals shares fell 6.31% today. A likely factor was JPMorgan analyst Jessica Fye maintaining an Overweight rating while lowering the firm’s price target from $375 to $369.

For informational and educational purposes only. Not financial advice.

#ALNY #BiotechStocks #HealthCare #MarketRecap

Category

🗞
News
Transcript
00:00Alnilam Pharmaceuticals fell 6.31% today. What happened?
00:05Alnilam Pharmaceuticals fell 6.31% today.
00:10In the preceding session, Benzinga reported that J.P. Morgan maintained its overweight rating,
00:16but lowered its price target from $375 to $369.
00:22The decline coincided with that reduced target,
00:26but no confirmed company-specific catalyst for today's full move was reported.
00:32More on software versus pharmaceuticals. Full recap linked.
Comments
After-the-fact Expert
Creator
Does JPMorgan’s lower price target change your view of Alnylam, or does the maintained Overweight rating matter more? Share what you think drove today’s selloff.

Recommended

  1. Quiet Pre-Market Trading Keeps Policy and Geopolitical Risks in Focus
    After-the-fact Expert
    8 hours ago
  2. Jabil Sinks 10.01% Despite Strong Outlook as Tech Splits the Market
    After-the-fact Expert
    1 day ago
  3. Hut 8 Slides 7.3% as the Market Weighs Financing and Insider Sale News
    After-the-fact Expert
    1 day ago
  4. Jabil Drops 10% Despite Strong Results and an Upbeat Outlook
    After-the-fact Expert
    1 day ago
  5. MARA Slides 5.67% With No Clear Catalyst
    After-the-fact Expert
    1 day ago
  6. ServiceNow Climbed 3.16% Today—But the Catalyst Remains Unclear
    After-the-fact Expert
    1 day ago
  7. Cerebras Systems Falls 4.65% as the Catalyst Remains Unclear
    After-the-fact Expert
    1 day ago
  8. Carnival Leads Cruise Rally as Meta Breaks Away From Apple
    After-the-fact Expert
    2 days ago
  9. Apple Slides 2.61% as AI Shopping Agents Raise App Store Concerns
    After-the-fact Expert
    2 days ago
  10. Meta Jumps 3.26% as Enterprise AI Interest Builds
    After-the-fact Expert
    2 days ago
  11. Royal Caribbean Jumps 7.46% as Cruise Stocks Rally
    After-the-fact Expert
    2 days ago
  12. AEHR Stock Went 21.5× — Can Its $100.6M Backlog Turn Into Revenue?
    After-the-fact Expert
    2 days ago
  13. Why AI Could Make Earlier Chip Testing More Valuable: The Aehr Test Systems Case
    After-the-fact Expert
    2 days ago
  14. Aehr Test Systems Relies on a Handful of Customers for Most of Its Revenue
    After-the-fact Expert
    2 days ago
  15. Aehr Test Systems: Four Numbers That Could Turn Promise Into Proof
    After-the-fact Expert
    2 days ago
  16. Where Aehr Test Systems Fits in the Chipmaking Process
    After-the-fact Expert
    2 days ago
  17. Aehr Test Systems Warns Its Backlog May Not Convert
    After-the-fact Expert
    2 days ago
  18. Aehr Test Systems Carries $100.6 Million in Orders After $50.0 Million Revenue Year
    After-the-fact Expert
    2 days ago
  19. Technology Fractures as MongoDB and Boeing Lead a Selective Selloff
    After-the-fact Expert
    3 days ago
  20. Intel Slides 5.59% as Chip-Sector Pressure Builds
    After-the-fact Expert
    3 days ago
  21. Palo Alto Networks Jumps 4.66%: What Drove PANW?
    After-the-fact Expert
    3 days ago
  22. MongoDB Drops 18.46% as Investors Assess Leadership Change
    After-the-fact Expert
    3 days ago
  23. Coeur Mining Leads a Cautious Pre-Market Watchlist as Major ETFs Slip
    After-the-fact Expert
    3 days ago
  24. Meta Falls 2.56% Pre-Market After September Surge
    After-the-fact Expert
    3 days ago
  25. Carnival Stock Jumps 13.55% After Strong Q3 Results
    After-the-fact Expert
    2 days ago